这个40岁的中年男人，只要面带微笑，平静地说出"我15天瘦了20斤"，桌面上就会爆发出此起彼伏的"我靠"——代表着惊讶和羡慕，以及随之而来的疑问： 到底是怎么做到的？ 以下文章来源于每日人物 ，作者每人作者 每日人物 . 轻商业，懂生活。 他总是隐隐地担心， 担心自己会为此付出代价。 文 ｜ 徐晴 编辑 ｜ 金匝 来源｜ 每日人物（ID：meirirenwu） 封面来源 ｜ 视觉中国 两个答案 于京掌握着一个让自己在饭局上成为话题中心的秘诀。 很多减肥的女性在漫长的身材焦虑期里，喝过三无减肥茶、酵素，试过催吐，或是坚持常年不吃晚饭——本质上，减肥是在伤害自己的身体，是对自己身体 的不接纳、不认可。没有经历过这些的男性，对伤害自己身体的动作更加敏感。 关 于这个问题，于京心里有两个答案。有一次，一个关系一般的同事问他，他很自然地回答说："减肥最基本的两个点，少吃，多动，很简单。"另一次， 是几个相识多年的好哥们问起，于京这才坦白，自己是打了司美格鲁肽——一种GLP-1受体激动剂，注射这种药物后，人可以长时间保持饱腹感，不想进 食，体重迅速减轻，某种程度上说，也算是"少吃"。 之所以有两个答案，是源于于京有一种微 ...

Group 1 - The core finding from the real-world study presented by Novo Nordisk at the EASD conference indicates that 46% of patients using semaglutide (brand name: Ozempic) reported a significant reduction in "food noise," which refers to uncontrollable thoughts about food [2] - Semaglutide, a GLP-1 drug, works by suppressing appetite, slowing gastric emptying, and inducing a feeling of fullness, thereby aiding weight loss [2] - Novo Nordisk's recent data shows that 84.5% of weight loss in patients was derived from body fat, preserving muscle function, which is crucial for maintaining overall health during weight loss [3] Group 2 - Novo Nordisk is actively addressing competition from Eli Lilly and has recently announced a large-scale global layoff, resulting in an over 11% increase in its stock price within a week [3] - The company aims to enhance decision-making efficiency and accelerate clinical pipeline progress, as stated by its Chief Scientific Officer Martin Holst Lange [3] - Novo Nordisk is exploring treatments for various obesity-related complications and is validating the efficacy of its weight loss drug for Alzheimer's disease, with expectations to obtain clinical data by the end of 2025 [3] - Positive clinical trial results for the Alzheimer's study could potentially generate up to $15 billion in additional annual revenue for Novo Nordisk, according to UBS analysis [3]

Core Insights - Novo Nordisk presented real-world research results on the use of semaglutide for weight loss at the EASD annual meeting, indicating that 46% of patients reported a significant reduction in "food noise" after treatment [1][3] - The company reported that 84.5% of weight loss from semaglutide comes from body fat, preserving muscle function, which is crucial for overweight or obese patients [3] - Novo Nordisk is facing competition from Eli Lilly and has recently announced significant layoffs, resulting in an over 11% increase in stock price within a week [3] - The company is exploring treatments for various obesity-related conditions and is validating the efficacy of its weight loss drug for Alzheimer's disease, with potential annual revenue of up to $15 billion if clinical trials succeed [4] Company Developments - Novo Nordisk aims to enhance decision-making efficiency and accelerate clinical pipeline progress following recent layoffs [3] - The company is developing therapies targeting a range of conditions associated with obesity, including arthritis and sleep apnea [4] - The ongoing large-scale clinical study for Alzheimer's disease is the first of its kind for GLP-1 drugs, with results expected by the end of 2025 [4]

Group 1 - Meituan's pharmaceutical health division has launched a new insomnia treatment drug, Lemborexant, which is the first approved dual orexin receptor antagonist, providing a new treatment option for adult insomnia patients [1] - The drug is not classified as a controlled substance and has not shown addictive properties since its launch [1] - According to the "2025 China Sleep Health Survey Report," approximately 485 million people in China suffer from sleep issues, highlighting the significant market potential for insomnia treatments [1] Group 2 - Meituan has actively introduced innovative drug products, having launched seven new drugs since last year, including Lemborexant, covering various medical fields such as GLP-1, myopia, gout, and insomnia [2] - The company aims to enhance the accessibility of innovative drugs through its e-commerce platform, allowing patients to order medications conveniently [2]

Group 1 - The increasing awareness of obesity as a chronic disease and its health risks has led to a growing demand for weight management solutions in China, with a projected adult overweight and obesity rate of 70.5% by 2030 if not effectively addressed [1] - The GLP-1 class of innovative drugs is becoming a focal point for pharmaceutical companies, with significant competition in drug development aimed at treating obesity and overweight conditions [1] - Online platforms are being recognized for their value in connecting patients with medications and providing professional health support services, influencing pharmaceutical companies' partnership selections [1] Group 2 - JD Health successfully launched the weight loss drug Ma Shidu (generic name: Magsduptide injection) on its platform shortly after its approval, marking a significant entry into the weight loss market [2][3][4] - Ma Shidu has four key advantages over previous weight loss medications, including effective improvement of fatty liver disease, clinical trials based on Chinese populations, enhanced convenience and safety in administration, and ongoing clinical trials for various demographics [5] - The collaboration between JD Health and pharmaceutical companies reflects a mutual interest in leveraging online channels for drug sales and health management, with JD Health's platform being a critical player in this transition [6][8] Group 3 - JD Health's partnerships with major pharmaceutical companies, such as the strategic agreement with Novo Nordisk, highlight the shift from merely selling drugs to managing health, emphasizing the importance of online platforms in the healthcare ecosystem [6][9] - The online platform has seen significant user engagement, with nearly 300,000 users purchasing GLP-1 medications during the 618 shopping festival, indicating a threefold increase in sales [9] - JD Health has introduced a multidisciplinary "weight loss clinic" to provide comprehensive services, integrating various medical specialties to support users in their weight management journey [10] Group 4 - The complexity and instability of peptide drugs necessitate stringent cold chain logistics for safe storage and transportation, which has become a competitive factor for online channels [11] - JD Logistics has established a nationwide cold chain distribution network, improving delivery efficiency and ensuring compliance with storage regulations, contributing to JD Health's leading market share of over 70% in the online weight loss category [11]

Core Viewpoint - GLP-1 (glucagon-like peptide-1) plays a crucial role in regulating blood sugar and controlling weight, with significant advancements in the development of GLP-1 drugs globally, particularly focusing on oral formulations like Rybelsus [2][4][6] Group 1: GLP-1 Overview - GLP-1 is secreted by intestinal L cells and helps in slowing gastric motility, prolonging gastric emptying time, and effectively suppressing appetite [2] - Notable GLP-1 drugs include Semaglutide (Ozempic for diabetes, Wegovy for weight loss, and Rybelsus as the first oral GLP-1 receptor agonist) and Tirzepatide (Mounjaro) [2][4] Group 2: Rybelsus Advantages - Rybelsus offers convenience as an oral medication, eliminating the need for refrigeration and improving patient adherence due to accurate dosing [4] - The formulation includes Semaglutide and an absorption enhancer (SNAC), which increases the bioavailability of the drug by approximately 100 times [4] Group 3: Clinical Research and Efficacy - The global Phase III clinical trial PIONEER involved 11,505 patients and confirmed the efficacy and safety of oral Semaglutide, showing significant reductions in blood sugar and weight [6] - In China, the HbA1c target achievement rate for newly diagnosed type 2 diabetes patients using Rybelsus monotherapy reached 92.3% [6] Group 4: Comparison of Formulations - Ozempic (injection for diabetes) and Wegovy (injection for weight loss) have similar efficacy profiles to Rybelsus, which is an oral formulation [7][8][9] - Clinical trials indicate that Rybelsus can potentially replace injection forms without dosage adjustments, providing a "pain-free" weight loss option [12] Group 5: Weight Loss Outcomes - In clinical trials, Rybelsus demonstrated significant weight loss, with a 68-week study showing an average weight reduction of 17.4% (18.34 kg) in obese patients [10] - The OASIS 4 study indicated that patients on 25 mg oral Semaglutide lost an average of 13.6% (14.4 kg) of their body weight over 64 weeks [16] Group 6: Safety and Tolerability - While oral Semaglutide shows similar efficacy to injection forms, higher doses (25 mg and 50 mg) may be required to achieve comparable weight loss results [14][15] - Safety concerns include a 14% incidence of "skin sensation abnormalities" at the 50 mg dose, which were not reported in injection forms [15]

Core Viewpoint - Changshan Pharmaceutical has seen its stock price surge nearly 200% in two months, leading to its recognition as the "first innovative drug stock" in A-shares for 2025, despite reporting losses for two consecutive years and primarily relying on heparin products [1][2]. Group 1: Stock Performance and Market Sentiment - The stock price of Changshan Pharmaceutical reached a new high of 52.09 yuan on June 9, with a market capitalization approaching 480 billion yuan, significantly distancing itself from its competitor, Hepalink [2]. - The divergence between the company's poor financial performance and its soaring stock price is notable, with projected net losses of 12.40 billion yuan and 2.49 billion yuan for 2023 and 2024, respectively, while the stock price is expected to increase by 137.41% and 53.65% in the same years [2][3]. Group 2: Product Development and Market Competition - Changshan Pharmaceutical heavily relies on its heparin business, with nearly 87% of its revenue in 2024 coming from various heparin products, which has been negatively impacted by the absence of its main product in national bulk procurement [3]. - The company has been developing a GLP-1 class drug, Aibennate Injection, which is currently in the registration phase, but it faces significant market competition and uncertainty regarding profitability [3][4]. - The Aibennate Injection is a long-acting GLP-1 receptor agonist intended for the treatment of type 2 diabetes, but the company has cautioned investors about the competitive landscape and the uncertain nature of its market entry [3][4]. Group 3: Clinical Data and Future Prospects - As of now, there is limited clinical data available for Aibennate Injection, which has only been reported for the type 2 diabetes indication, raising concerns about its competitive edge in the market [7]. - The market for oral GLP-1 drugs is seen as promising due to the lower adherence rates of current injectable options, suggesting a potential opportunity for companies that can balance safety and efficacy in their products [7].